RESUMO
Bone cancer pain is common among cancer patients and can have a devastating effect on their quality of life. A chief problem in designing new therapies for bone cancer pain is that it is unclear what mechanisms drive this distinct pain condition. Here we show that osteoprotegerin, a secreted 'decoy' receptor that inhibits osteoclast activity, also blocks behaviors indicative of pain in mice with bone cancer. A substantial part of the actions of osteoprotegerin seems to result from inhibition of tumor-induced bone destruction that in turn inhibits the neurochemical changes in the spinal cord that are thought to be involved in the generation and maintenance of cancer pain. These results demonstrate that excessive tumor-induced bone destruction is involved in the generation of bone cancer pain and that osteoprotegerin may provide an effective treatment for this common human condition.
Assuntos
Desmineralização Patológica Óssea/tratamento farmacológico , Glicoproteínas/uso terapêutico , Osteossarcoma/complicações , Dor/tratamento farmacológico , Receptores Citoplasmáticos e Nucleares , Medula Espinal/efeitos dos fármacos , Animais , Astrócitos/efeitos dos fármacos , Comportamento Animal/efeitos dos fármacos , Membro Posterior/patologia , Masculino , Camundongos , Camundongos Endogâmicos C3H , Osteoclastos/efeitos dos fármacos , Osteoprotegerina , Receptores do Fator de Necrose Tumoral , Sarcoma Experimental/complicaçõesRESUMO
Substance P receptor (SPR)-expressing spinal neurons were ablated with the selective cytotoxin substance P-saporin. Loss of these neurons resulted in a reduction of thermal hyperalgesia and mechanical allodynia associated with persistent neuropathic and inflammatory pain states. This loss appeared to be permanent. Responses to mildly painful stimuli and morphine analgesia were unaffected by this treatment. These results identify a target for treating persistent pain and suggest that the small population of SPR-expressing neurons in the dorsal horn of the spinal cord plays a pivotal role in the generation and maintenance of chronic neuropathic and inflammatory pain.
Assuntos
Imunotoxinas , N-Glicosil Hidrolases , Dor/tratamento farmacológico , Dor/fisiopatologia , Proteínas de Plantas/farmacologia , Células do Corno Posterior/fisiologia , Receptores da Neurocinina-1/metabolismo , Substância P/farmacologia , Animais , Relação Dose-Resposta a Droga , Gânglios Espinais/efeitos dos fármacos , Gânglios Espinais/fisiologia , Inflamação/fisiopatologia , Ligadura , Neuralgia/tratamento farmacológico , Neuralgia/fisiopatologia , Proteínas de Plantas/administração & dosagem , Células do Corno Posterior/efeitos dos fármacos , Ratos , Proteínas Inativadoras de Ribossomos Tipo 1 , Saporinas , Nervos Espinhais , Substância P/administração & dosagem , Fatores de TempoRESUMO
Bone cancer pain most commonly occurs when tumors originating in breast, prostate, or lung metastasize to long bones, spinal vertebrae, and/or pelvis. Primary and metastatic cancers involving bone account for approximately 400,000 new cancer cases per year in the United States alone, and >70% of patients with advanced breast or prostate cancer have skeletal metastases. Whereas pain resulting from bone cancer can dramatically impact an individual's quality of life, very little is known about the mechanisms that generate and maintain this pain. To begin to define the mechanisms that give rise to advanced bone cancer pain, osteolytic 2472 sarcoma cells or media were injected into the intramedullary space of the femur of C3H/HeJ mice, and the injection hole was sealed using dental amalgam, confining the tumor cells to the bone. Twelve days after injection of 2472 tumor cells, animals showed advanced tumor-induced bone destruction of the injected femur, bone cancer pain, and a stereotypic set of neurochemical changes in the spinal cord dorsal horn that receives sensory inputs from the affected femur. Administration of osteoprotegerin, a naturally secreted decoy receptor that inhibits osteoclast maturation and activity and induces osteoclast apoptosis, or vehicle was begun at 12 days, when significant bone destruction had already occurred, and administration was continued daily until day 21. Ongoing pain behaviors, movement-evoked pain behaviors, and bone destruction were assessed on days 10, 12, 14, 17, and 21. The neurochemistry of the spinal cord was evaluated at days 12 and 21. Results indicated that osteoprotegerin treatment halted further bone destruction, reduced ongoing and movement-evoked pain, and reversed several aspects of the neurochemical reorganization of the spinal cord. Thus, even in advanced stages of bone cancer, ongoing osteoclast activity appears to be involved in the generation and maintenance of ongoing and movement-evoked pain. Blockade of ongoing osteoclast activity appears to have the potential to reduce bone cancer pain in patients with advanced tumor-induced bone destruction.
Assuntos
Neoplasias Ósseas/complicações , Glicoproteínas/farmacologia , Dor/tratamento farmacológico , Animais , Neoplasias Ósseas/patologia , Modelos Animais de Doenças , Masculino , Camundongos , Camundongos Endogâmicos C3H , Neurônios Aferentes/metabolismo , Neurônios Aferentes/fisiologia , Osteoclastos/efeitos dos fármacos , Osteoclastos/fisiologia , Osteólise/complicações , Osteólise/tratamento farmacológico , Osteólise/etiologia , Osteoprotegerina , Dor/etiologia , Proteínas Proto-Oncogênicas c-fos/biossíntese , Receptores Citoplasmáticos e Nucleares , Receptores do Fator de Necrose Tumoral , Sarcoma Experimental/complicações , Sarcoma Experimental/patologia , Medula Espinal/efeitos dos fármacos , Medula Espinal/patologiaRESUMO
Tumors including sarcomas and breast, prostate, and lung carcinomas frequently grow in or metastasize to the skeleton where they can induce significant bone remodeling and cancer pain. To define products that are released from tumors that are involved in the generation and maintenance of bone cancer pain, we focus here on endothelin-1 (ET-1) and endothelin receptors as several tumors including human prostate and breast have been shown to express high levels of ETs and the application of ETs to peripheral nerves can induce pain. Here we show that in a murine osteolytic 2472 sarcoma model of bone cancer pain, the 2472 sarcoma cells express high levels of ET-1, but express low or undetectable levels of endothelin A (ETAR) or B (ETBR) receptors whereas a subpopulation of sensory neurons express the ETAR and non-myelinating Schwann cells express the ETBR. Acute (10 mg/kg, i.p.) or chronic (10 mg/kg/day, p.o.) administration of the ETAR selective antagonist ABT-627 significantly attenuated ongoing and movement-evoked bone cancer pain and chronic administration of ABT-627 reduced several neurochemical indices of peripheral and central sensitization without influencing tumor growth or bone destruction. In contrast, acute treatment (30 mg/kg, i.p.) with the ETBR selective antagonist, A-192621 increased several measures of ongoing and movement evoked pain. As tumor expression and release of ET-1 has been shown to be regulated by the local environment, location specific expression and release of ET-1 by tumor cells may provide insight into the mechanisms that underlie the heterogeneity of bone cancer pain that is frequently observed in humans with multiple skeletal metastases.
Assuntos
Neoplasias Ósseas/metabolismo , Endotelina-1/fisiologia , Dor/metabolismo , Sarcoma/metabolismo , Análise de Variância , Animais , Atrasentana , Comportamento Animal , Neoplasias Ósseas/complicações , Neoplasias Ósseas/tratamento farmacológico , Peptídeo Relacionado com Gene de Calcitonina/metabolismo , Modelos Animais de Doenças , Dinorfinas/metabolismo , Antagonistas dos Receptores de Endotelina , Endotelina-1/sangue , Gânglios Espinais/metabolismo , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Proteína Glial Fibrilar Ácida/metabolismo , Imuno-Histoquímica/métodos , Masculino , Camundongos , Camundongos Endogâmicos , Dor/tratamento farmacológico , Dor/etiologia , Medição da Dor/efeitos dos fármacos , Pirrolidinas/uso terapêutico , Receptores de Endotelina/metabolismo , Sarcoma/complicações , Sarcoma/tratamento farmacológico , Nervo Isquiático/metabolismo , Fatores de TempoRESUMO
The aim of this investigation was to determine whether murine models of inflammatory, neuropathic and cancer pain are each characterized by a unique set of neurochemical changes in the spinal cord and sensory neurons. All models were generated in C3H/HeJ mice and hyperalgesia and allodynia behaviorally characterized. A variety of neurochemical markers that have been implicated in the generation and maintenance of chronic pain were then examined in spinal cord and primary afferent neurons.Three days after injection of complete Freund's adjuvant into the hindpaw (a model of persistent inflammatory pain) increases in substance P, calcitonin gene-related peptide, protein kinase C gamma, and substance P receptor were observed in the spinal cord. Following sciatic nerve transection or L5 spinal nerve ligation (a model of persistent neuropathic pain) significant decreases in substance P and calcitonin gene-related peptide and increases in galanin and neuropeptide Y were observed in both primary afferent neurons and the spinal cord. In contrast, in a model of cancer pain induced by injection of osteolytic sarcoma cells into the femur, there were no detectable changes in any of these markers in either primary afferent neurons or the spinal cord. However, in this cancer-pain model, changes including massive astrocyte hypertrophy without neuronal loss, increase in the neuronal expression of c-Fos, and increase in the number of dynorphin-immunoreactive neurons were observed in the spinal cord, ipsilateral to the limb with cancer. These results indicate that a unique set of neurochemical changes occur with inflammatory, neuropathic and cancer pain in C3H/HeJ mice and further suggest that cancer induces a unique persistent pain state. Determining whether these neurochemical changes are involved in the generation and maintenance of each type of persistent pain may provide insight into the mechanisms that underlie each of these pain states.
Assuntos
Neuralgia/metabolismo , Neurite (Inflamação)/metabolismo , Neurônios Aferentes/metabolismo , Dor/metabolismo , Sarcoma Experimental/metabolismo , Medula Espinal/metabolismo , Animais , Astrócitos/patologia , Axotomia , Comportamento Animal/fisiologia , Modelos Animais de Doenças , Dinorfinas/análise , Dinorfinas/metabolismo , Imunofluorescência , Adjuvante de Freund , Gânglios Espinais/metabolismo , Gânglios Espinais/patologia , Masculino , Camundongos , Camundongos Endogâmicos C3H , Transplante de Neoplasias , Neuralgia/induzido quimicamente , Neuralgia/patologia , Neurite (Inflamação)/patologia , Neurônios Aferentes/química , Osteólise/metabolismo , Osteólise/patologia , Dor/etiologia , Dor/patologia , Palpação , Estimulação Física , Proteínas Proto-Oncogênicas c-fos/análise , Proteínas Proto-Oncogênicas c-fos/metabolismo , Receptores da Neurocinina-1/análise , Receptores da Neurocinina-1/metabolismo , Sarcoma Experimental/complicações , Sarcoma Experimental/patologia , Nervo Isquiático/lesões , Nervo Isquiático/metabolismo , Medula Espinal/citologia , Nervos Espinhais/lesões , Nervos Espinhais/metabolismo , Células Tumorais Cultivadas/transplanteRESUMO
Although skeletal pain plays a major role in reducing the quality of life in patients suffering from osteoarthritis, Paget's disease, sickle cell anemia and bone cancer, little is known about the mechanisms that generate and maintain this pain. To define the peripheral fibers involved in transmitting and modulating skeletal pain, we used immunohistochemistry with antigen retrieval, confocal microscopy and three-dimensional image reconstruction of the bone to examine the sensory and sympathetic innervation of mineralized bone, bone marrow and periosteum of the normal mouse femur. Thinly myelinated and unmyelinated peptidergic sensory fibers were labeled with antibodies raised against calcitonin gene-related peptide (CGRP) and the unmyelinated, non-peptidergic sensory fibers were labeled with the isolectin B4 (Bandeira simplicifolia). Myelinated sensory fibers were labeled with an antibody raised against 200-kDa neurofilament H (clone RT-97). Sympathetic fibers were labeled with an antibody raised against tyrosine hydroxylase. CGRP, RT-97, and tyrosine hydroxylase immunoreactive fibers, but not isolectin B4 positive fibers, were present throughout the bone marrow, mineralized bone and the periosteum. While the periosteum is the most densely innervated tissue, when the total volume of each tissue is considered, the bone marrow receives the greatest total number of sensory and sympathetic fibers followed by mineralized bone and then periosteum. Understanding the sensory and sympathetic innervation of bone should provide a better understanding of the mechanisms that drive bone pain and aid in developing therapeutic strategies for treating skeletal pain.